Core Viewpoint - Tianchen Medical (688013) has shown a positive performance with a closing price of 50.8 yuan, reflecting a 1.6% increase as of August 27, 2025, amidst varying capital flows [1][2]. Financial Performance - The company reported a main revenue of 156 million yuan for the first half of 2025, representing a year-on-year increase of 17.66% [4]. - The net profit attributable to shareholders was 48.21 million yuan, up 67.1% year-on-year [4]. - The second quarter of 2025 saw a single-quarter main revenue of 90.32 million yuan, a 24.56% increase year-on-year, and a net profit of 35.02 million yuan, which is a 100.15% increase year-on-year [4]. Capital Flow Analysis - On August 27, 2025, the net outflow of main funds was 3.56 million yuan, accounting for 1.62% of the total transaction amount, while retail funds saw a net outflow of 495,300 yuan [1]. - Over the past five days, the financing balance increased to 128 million yuan, with a net financing purchase of 7.23 million yuan on August 27 [2]. Industry Comparison - Tianchen Medical's total market value is 4.123 billion yuan, significantly lower than the industry average of 12.081 billion yuan, ranking 89th out of 123 in the medical device industry [4]. - The company's net profit margin stands at 30.87%, which is considerably higher than the industry average of 11.01%, ranking 14th in the industry [4]. - The company's gross margin is 63.03%, surpassing the industry average of 51.64%, ranking 44th in the industry [4].

Company Performance - In the first half of 2025, the company achieved revenue of 156 million yuan, representing a year-on-year growth of 17.66% [1] - The net profit attributable to shareholders was 48.21 million yuan, with a year-on-year increase of 67.10% [1] R&D and Product Development - The company focuses on key surgical procedures, with core products including various types of surgical staplers and support products, addressing clinical needs such as tissue separation, excision, organ function reconstruction, and intraoperative hemostasis [2] - The main revenue driver is the minimally invasive endoscopic products, which include disposable endoscopic cutting staplers and electric endoscopic cutting staplers, widely used in various minimally invasive surgeries [2] - R&D investment reached 18.89 million yuan in the first half of 2025, up 21.34% year-on-year, with R&D expenditure accounting for 12.10% of revenue [2] - The company applied for 11 new patents globally and received 53 new patent authorizations, including 44 core technology invention patents [2] Product Pipeline and Market Expansion - The company is accelerating its layout around "ultra-minimally invasive + intelligent" dual lines, with products like the "TSN electric stapler" already registered in two overseas countries [3] - The "third-generation endoscopic cutting stapler and nail warehouse" has completed multiple rounds of testing and is about to enter the registration process [3] - The company is also advancing its smart surgical platform project, which has made significant progress in key technologies and is entering the first product release and industrialization phase [3] Industry Outlook - The global medical device market is projected to reach 623 billion USD by 2024, with a compound annual growth rate (CAGR) of 6.9% from 2019 to 2024, and expected to grow to 869.7 billion USD by 2030 [4] - The demand for minimally invasive and robotic surgeries is driving significant growth in the surgical instrument sector, with the company well-positioned to benefit from this trend due to its technological and patent advantages [4] Strategic Initiatives - The company is enhancing its domestic and overseas dual-drive strategy, ensuring stable supply of selected products under national procurement policies while dynamically assessing market competition [5] - The company plans to issue a high dividend payout, distributing 5 yuan per 10 shares, totaling 40.33 million yuan, which accounts for 83.66% of the net profit attributable to shareholders for the first half of the year [5][6]

Group 1 - Aofei Data achieved a net profit of 87.89 million yuan in the first half of 2025, a year-on-year increase of 16.09% [1] - Aofei Data's revenue for the same period was 1.148 billion yuan, up 8.20% year-on-year [1] - The company specializes in IDC services, internet business, system integration, and distributed photovoltaic energy-saving services [1] Group 2 - Meilan De reported a net profit of 63.92 million yuan, a year-on-year decrease of 11.96% [1] - The company's revenue was 241 million yuan, reflecting a growth of 5.62% year-on-year [1] - Meilan De focuses on the research, production, sales, and service of medical devices related to pelvic and obstetric rehabilitation [1] Group 3 - Jiuan Medical posted a net profit of 920 million yuan, a significant year-on-year increase of 52.91% [1] - The company's revenue decreased by 43.35% to 765 million yuan [1] - Jiuan Medical specializes in the research, production, and sales of home medical devices [2] Group 4 - Hanbang Technology's net profit fell by 26.24% to 27.80 million yuan [2] - The company achieved a revenue of 349 million yuan, a growth of 5.99% year-on-year [2] - Hanbang Technology provides professional separation and purification equipment, consumables, and technical solutions for the pharmaceutical and life sciences sectors [2] Group 5 - Jinjing Environment reported a net profit of 78.69 million yuan, a year-on-year increase of 13.73% [2] - The company's revenue was 782 million yuan, reflecting a growth of 1.70% [2] - Jinjing Environment focuses on investment operation management services and equipment manufacturing in the environmental sanitation sector [2] Group 6 - Tianbao Infrastructure achieved a net profit of 118 million yuan, a remarkable year-on-year increase of 2106.58% [3] - The company's revenue decreased by 8.31% to 486 million yuan [3] - Tianbao Infrastructure is involved in real estate development, property leasing, and management [4] Group 7 - Weihuaxin Materials reported a net profit of 83.15 million yuan, a year-on-year decrease of 52.91% [5] - The company's revenue was 437 million yuan, down 30.71% year-on-year [5] - Weihuaxin Materials specializes in the research and production of chlorotoluene and trifluoromethylbenzene products [5] Group 8 - Tianchen Medical posted a net profit of 48.21 million yuan, a year-on-year increase of 67.10% [6] - The company's revenue was 156 million yuan, reflecting a growth of 17.66% [6] - Tianchen Medical focuses on the research, innovation, and production of high-end surgical staplers [6] Group 9 - Greenland Holdings reported a net loss of 3.506 billion yuan in the first half of 2025 [8] - The company's revenue was 9.45 billion yuan, down 18.06% year-on-year [8] - Greenland Holdings is involved in various financial services including securities, futures, and trust [8] Group 10 - Wukuang Capital's net profit decreased by 41.47% to 525 million yuan [9] - The company achieved a total revenue of 623 million yuan, a significant increase of 144.86% [9] - Wukuang Capital operates in the financial sector, providing services such as securities and leasing [9] Group 11 - Yutong Technology reported a net profit of 554 million yuan, a year-on-year increase of 11.42% [10] - The company's revenue was 7.876 billion yuan, reflecting a growth of 7.10% [10] - Yutong Technology specializes in the research, design, production, and sales of paper packaging products [10] Group 12 - Wewei Co. posted a net profit of 120 million yuan, a year-on-year decrease of 20.14% [11] - The company's revenue was 1.521 billion yuan, down 12.76% year-on-year [11] - Wewei Co. focuses on the production and sales of various food and beverage products [11] Group 13 - Tongfang Co. reported a net loss of 256 million yuan in the first half of 2025 [12] - The company's revenue was 5.667 billion yuan, down 10.09% year-on-year [12] - Tongfang Co. is engaged in the development of smart technology and nuclear technology applications [12] Group 14 - Liugang Co. achieved a net profit of 368 million yuan, a year-on-year increase of 579.54% [13] - The company's revenue was 34.675 billion yuan, down 8.32% [13] - Liugang Co. specializes in coke, sintering, iron, steel smelting, and steel processing [13] Group 15 - China National Petroleum Corporation reported a net profit of 83.993 billion yuan, with a proposed dividend of 0.22 yuan per share [14] - The company's revenue was 1.45 trillion yuan, down 6.7% year-on-year [14] - The company is involved in oil and gas exploration, production, refining, and sales [14] Group 16 - Fangda Carbon's net profit decreased by 68.31% to 54.53 million yuan [15] - The company's revenue was 1.690 billion yuan, down 28.13% year-on-year [15] - Fangda Carbon specializes in the research, production, and sales of graphite and carbon materials [15] Group 17 - Xinmai Medical reported a net profit of 31.5 million yuan, a year-on-year decrease of 22.03% [18] - The company's revenue was 714 million yuan, down 9.24% year-on-year [18] - Xinmai Medical focuses on the research, production, and sales of vascular intervention medical devices [18] Group 18 - Hengbao Co. posted a net profit of 35.35 million yuan, a year-on-year decrease of 44.41% [19] - The company's revenue was 430 million yuan, down 8.64% year-on-year [19] - Hengbao Co. specializes in high-end intelligent products and digital security solutions [19] Group 19 - Zhongji Xuchuang reported a net profit of 3.995 billion yuan, a year-on-year increase of 69.40% [20] - The company's revenue was 14.789 billion yuan, reflecting a growth of 36.95% [20] - Zhongji Xuchuang specializes in high-end optical communication modules and devices [20] Group 20 - Guangxian Media achieved a net profit of 2.229 billion yuan, a year-on-year increase of 371.55% [21] - The company's revenue was 3.242 billion yuan, up 143.00% year-on-year [21] - Guangxian Media focuses on investment, production, and distribution of film projects [21] Group 21 - Huarun Pharmaceutical reported a net profit of 37.33 million yuan, a year-on-year decrease of 49.01% [23] - The company's revenue was 624 million yuan, down 19.13% year-on-year [23] - Huarun Pharmaceutical specializes in pharmaceuticals, medical devices, and health products [23] Group 22 - Huawai Technology posted a net profit of 12.7 million yuan, a year-on-year increase of 56.18% [24] - The company's revenue was 937 million yuan, reflecting a growth of 32.62% [24] - Huawai Technology focuses on the research, production, and sales of high-end elastic components [24]

公司最新总资产周转率为0.24次，在已披露的同业公司中排名第15，较去年同期总资产周转率增加0.04次，同比较去年同期上涨17.61%。最新存货周转率为 1.59次，在已披露的同业公司中排名第16。 公司股东户数为4148户，前十大股东持股数量为4713.21万股，占总股本比例为58.08%，前十大股东持股情况如下： 公司最新毛利率为63.04%，在已披露的同业公司中排名第24，较上季度毛利率增加4.58个百分点，较去年同期毛利率增加5.00个百分点，实现2年连续上 涨。最新ROE为8.39%，在已披露的同业公司中排名第8，较去年同期ROE增加3.58个百分点。 公司摊薄每股收益为0.60元，在已披露的同业公司中排名第17，较去年同报告期摊薄每股收益增加0.24元，实现3年连续上涨，同比较去年同期上涨 66.67%。 2025年8月27日，天臣医疗(688013.SH)发布2025年中报。 公司营业总收入为1.56亿元，较去年同报告期营业总收入增加2343.50万元，实现5年连续上涨，同比较去年同期上涨17.66%。归母净利润为4821.16万元，较 去年同报告期归母净利润增加1936.03万元，实现3年连续 ...

证券之星消息，截至2025年8月26日收盘，天臣医疗(688013)报收于50.0元，上涨10.5%，换手率5.6%， 成交量4.55万手，成交额2.19亿元。 8月26日的资金流向数据方面，主力资金净流入1811.8万元，占总成交额8.29%，游资资金净流出145.53 万元，占总成交额0.67%，散户资金净流出1666.27万元，占总成交额7.62%。 近5日资金流向一览见下表： | 日期 | 涨跌幅 | 融资余额(元) | 融资净买入(元) | 融券余重(股) | 融券净卖出(股) | 融资融券余额(元) | | --- | --- | --- | --- | --- | --- | --- | | 2025-08-26 | 10.50% | 1.21亿 | 712.46万 | 0.0 | 0.0 | 1.21亿 | | 2025-08-25 | 6.07% | 1.14亿 | 470.77万 | 0.0 | 0.0 | 1.14亿 | | 2025-08-22 | 3.42% | 1.09亿 | 255.25万 | 0.0 | 0.0 | 1.09 乙 | | 2025-08-21 | 3.44% | ...

Group 1: AI Medical - Ping An Good Doctor's stock surged by 6.99% on August 26, with its price doubling in the past month. The company reported an AI product system "7+N+1" with an accuracy rate of approximately 98% for AI-assisted consultations and nearly 80% for complex disease treatment plans [4] - The average service cost for family doctors decreased by about 52% due to AI assistance, and operational efficiency improved by around 50% [4] Group 2: Artificial Intelligence Policy - The State Council released an opinion on August 26 to implement the "Artificial Intelligence+" initiative, aiming for over 70% application penetration of new intelligent terminals and agents by 2027, and over 90% by 2030 [5] - The initiative includes building national AI application pilot bases and promoting the transformation of software and information service companies [5] Group 3: 5.5G Development - The Ministry of Industry and Information Technology is expected to issue the second batch of millimeter-wave private network frequency licenses, with more companies anticipated to receive licenses by the end of the year [6] - This issuance indicates the maturity of the domestic millimeter-wave 5G industry chain and is expected to initiate a wave of innovation in the sector [7] Group 4: Gaming Industry - The National Press and Publication Administration approved 173 games in August 2025, setting a new record for the year, including 166 domestic and 7 imported games [9] - The gaming market is projected to maintain long-term optimistic growth, with the 3A game market expected to reach 13.3 billion yuan in 2025 and 16.9 billion yuan in 2026, with a CAGR of 35% anticipated from 2027 to 2028 [9] Group 5: Company Earnings - Cambrian reported a net profit of 1.038 billion yuan in the first half of 2025, compared to a loss of 530 million yuan in the same period last year [12] - North Rare Earth's net profit surged by 1951.52% year-on-year to 931 million yuan in the first half of 2025 [12] - Light Media's net profit increased by 371.55% year-on-year to 2.229 billion yuan in the first half of 2025 [12]

截至2025年8月26日收盘，天臣医疗(688013)报收于50.0元，上涨10.5%，换手率5.6%，成交量4.55万 手，成交额2.19亿元。 当日关注点 交易信息汇总 8月26日，天臣医疗的资金流向显示，主力资金净流入1811.8万元，占总成交额8.29%；游资资金净流出 145.53万元，占总成交额0.67%；散户资金净流出1666.27万元，占总成交额7.62%。 公司公告汇总天臣医疗2025年半年度报告摘要 天臣国际医疗科技股份有限公司2025年半年度报告摘要显示，公司2025年上半年实现营业收入 156168251.45元，同比增长17.66%；归属于上市公司股东的净利润48211574.09元，同比增长67.10%。 公司拟向全体股东每10股派发现金红利5.00元（含税），合计拟派发现金红利40331769.50元（含税）， 占公司2025年半年度合并报表归属于上市公司股东净利润的比例为83.66%。该预案尚需提交公司2025 年第三次临时股东大会审议。 关于召开2025年第三次临时股东会的通知 天臣医疗将于2025年9月12日召开第三次临时股东会，采用现场投票和网络投票相结合的方式。现场会 ...

| 证券代码：688013 证券简称：天臣医疗 公告编号：2025-048 | | | | | --- | --- | --- | --- | | 天臣国际医疗科技股份有限公司 | | | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 | | | | | 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | | | 根据中国证券监督管理委员会《上市公司募集资金监管规则》和《上海证券 | | | | | 交易所科创板上市公司自律监管指引第 1 号——规范运作》及相关格式指引等有 | | | | | 关规定，天臣国际医疗科技股份有限公司（以下简称"天臣医疗"、"公司"或"本 | | | | | 公司"）董事会编制了 2025 年半年度募集资金存放与实际使用情况专项报告。 | | | | | 一、募集资金基本情况 | | | | | （一）实际募集资金金额及到账时间 | | | | | 天臣医疗经中国证券监督管理委员会《关于同意天臣国际医疗科技股份有限 | | | | | 公司首次公开发行股票注册的批复》（证监许可[2020]2020 号）核准，公司向社 | ...

证券代码：688013 证券简称：天臣医疗 公告编号：2025-050 天臣国际医疗科技股份有限公司 关于 2025 年半年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股分配比例：每 10 股派发现金红利 5.00 元（含税），不进行资本公 积金转增股本，不送红股。 本次利润分配以实施权益分派股权登记日登记的总股本扣减公司回购专 用证券账户中股份为基数分配利润，具体日期将在权益分派实施公告中明确。 如在公告披露之日起至实施权益分派股权登记日期间，公司总股本扣除 公司回购专用账户中股份的基数发生变动的，公司拟维持每股分配金额不变， 相应调整分配总额，并将另行公告具体调整情况。 本次利润分配方案尚需提交公司 2025 年第三次临时股东会审议通过后 方可实施。 一、利润分配方案内容 截至 2025 年 6 月 30 日，天臣国际医疗科技股份有限公司（以下简称"公 司"）期末母公司报表中可供分配利润为 93,964,559.42 元（未经审计），2025 年 半年度实现归属于母公司所有者 ...

格隆汇8月26日丨天臣医疗(688013.SH)发布中报，2025上半年实现营业总收入1.56亿元，同比增长 17.66%；归属母公司股东净利润4821.16万元，同比增长67.1%；基本每股收益为0.6元。此外，拟对全 体股东每10股派发现金红利5元(含税)。 ...